title: [Changes in blood polyamine levels following chemotherapy in patients with invasive urinary bladder carcinoma].
abstract: BACKGROUND
  Polyamines are recognized as cell growth factors. We attempted to determine whether blood polyamines are useful biochemical makers for monitoring the efficacy of the chemotherapy on bladder tumors.
  
  
  METHODS
  The blood concentrations of three polyamines, diamine, spermidine and spermine, were determined in 31 patients with invasive urinary bladder carcinoma, following chemotherapy with cisplatin, methotrexate and pirarubicin. Clinical response was evaluated by CT after 3 weeks. In 26 patients who underwent subsequent surgical therapy, the effectiveness of the chemotherapy were histopathologically evaluated by a pathologist according to the response criteria for bladder cancer treatment.
  
  
  RESULTS
  Mean regression rate in the size of the tumor after the chemotherapy was 40.8%. Of 31 patients, clinical CR was observed in 2, PR in 11, and NC in 18. Of 26 patients who were histopathologically evaluated, grade 3 was observed in 5, grade 2 in 4, grade 1b in 4, grade 1a in 12, and grade 0 in 1. One week after chemotherapy, the levels of spermine and total polyamine in the patients with CR and PR were significantly lower than those in the patients with NC. Similarly one week after chemotherapy, the levels of spermine and total polyamine in the patients with grade 3 and grade 2 were significantly lower than those in the patients with grade 1b, grade 1a and grade 0.
  
  
  CONCLUSIONS
  The study suggested that the levels of blood polyamines could be used as biochemical markers for monitoring the efficacy of the chemotherapy on bladder tumors.
authors.affiliation: Department of Urology, Gifu Prefectural Gifu Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Taniguchi
authors.forename: K
authors.initials: K
authors.lastname: Minoshima
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: S
authors.initials: S
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Deguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kawada
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: A
authors.initials: A
authors.lastname: Hara
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000097:blood / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011073:Polyamines / Q000097:blood*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000188:drug therapy*
chemical_list: D014408:Biomarkers, Tumor; D011073:Polyamines; D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin; D008727:Methotrexate